CTLA4Fcε, a novel soluble fusion protein that binds B7 molecules and the IgE receptors, and reduces human in vitro soluble CD23 production and lymphocyte proliferation.

@article{PerezWitzke2016CTLA4FcAN,
  title={CTLA4Fcε, a novel soluble fusion protein that binds B7 molecules and the IgE receptors, and reduces human in vitro soluble CD23 production and lymphocyte proliferation.},
  author={Daniel Perez-Witzke and Mar{\'i}a Auxiliadora Miranda-Garc{\'i}a and Nuris Su{\'a}rez and Raquel Becerra and Kharelys Duque and Ver{\'o}nica Porras and Jaheli Fuenmayor and Ramon Fernando Montano},
  journal={Immunology},
  year={2016},
  volume={148 1},
  pages={40-55}
}
Immunoglobulin E-mediated allergy and certain autoimmune diseases are characterized by the presence of a T helper type 2 (Th2) immune response and allergen-specific or self-reactive IgE. Soluble CD23 (sCD23) is a B-cell factor that fosters IgE class-switching and synthesis, suggesting that sCD23 may be a therapeutic target for these pathologies. We produced a recombinant protein, CTLA4Fcε, by fusing the ectodomain of the immunoregulatory molecule cytotoxic T-lymphocyte antigen 4 (CTLA-4) with a… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

References

Publications referenced by this paper.
Showing 1-10 of 74 references

Pharmacoki - netics , pharmacodynamics and safety of QGE 031 ( ligelizumab ) , a novel high - affinity antiIgE antibody , in atopic subjects

JP Arm, L Bottoli, +3 authors S Maahs
Clin Exp Allergy • 2014

anti-IgE antibody, in atopic subjects

Stokes, TB Casale
Clin Exp Allergy • 2014

Allergy Asthma Rep 2013; 13:281–7

H Kikutani, M Suemura, +3 authors K Yamasaki
Fce recep- • 2013

What is the source of serum allergenspecific IgE ?

J Eckl-Dorna, V Niedelberger
Curr Allergy Asthma Rep • 2013

Similar Papers

Loading similar papers…